ADXN vs INVA vs ABBV vs MRK

For growth investors, Innoviva, Inc.

(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus -74. 9% for Addex Therapeutics Ltd (ADXN). Addex Therapeutics Ltd (ADXN) offers the better valuation at 0. 7x trailing P/E, making it the more compelling value choice. Analysts rate Innoviva, Inc. (INVA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Addex Therapeutics Ltd (ADXN) is the cheapest at 0.

7x versus AbbVie Inc. at 85. 5x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Merck & Co. , Inc. wins at 1. 03x versus Innoviva, Inc. 's 1. 15x — a reasonable growth-adjusted valuation.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -96. 5% for Addex Therapeutics Ltd (ADXN). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus ADXN's -96. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Addex Therapeutics Ltd's 0. 59β — meaning ADXN is approximately 368% more volatile than INVA relative to the S&P 500. On balance sheet safety, Addex Therapeutics Ltd (ADXN) carries a lower debt/equity ratio of 0% versus 96% for Merck & Co. , Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Innoviva, Inc.

(INVA) is pulling ahead at 18. 5% versus -74. 9% for Addex Therapeutics Ltd (ADXN). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, INVA leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Addex Therapeutics Ltd (ADXN) is the more profitable company, earning 1746% net margin versus 6.

9% for AbbVie Inc. — meaning it keeps 1746% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -681. 8% for ADXN. At the gross margin level — before operating expenses — ADXN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Merck & Co. , Inc. (MRK) is the more undervalued stock at a PEG of 1. 03x versus Innoviva, Inc. 's 1. 15x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Innoviva, Inc. (INVA) trades at 11. 9x forward P/E versus 21. 9x for Merck & Co. , Inc. — 10. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 65. 2% to $37. 67.

In this comparison, ABBV (3.

2% yield), MRK (2. 9% yield) pay a dividend. ADXN, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, ADXN: -96. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ADXN is a small-cap deep-value stock; INVA is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock; MRK is a large-cap deep-value stock. ABBV, MRK pay a dividend while ADXN, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.